Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells

Cell Cycle

Volumn 11, Issue 19, 2012, Pages 3649-3655

  Iwai, Aki ^a   Bourboulia, Dimitra ^a   Mollapour, Mehdi ^a   Jensen Taubman, Sandra ^a   Lee, Sunmin ^a   Donnelly, Alison C ^b   Yoshida, Soichiro ^a   Miyajima, Naoto ^a   Tsutsumi, Shinji ^a   Smith, Armine K ^a   Sun, David ^c   Wu, Xiaolin ^c   Blagg, Brian S ^b   Trepel, Jane B ^a   Stetler Stevenson, William G ^a   Neckers, Len ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c SAIC FREDERICK INC   (United States)

Author keywords

Apoptosis; Cancer; Heat shock protein 90; Molecular targeted anticancer drugs; Wee1

Indexed keywords

GANETESPIB; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN WEE1; PROTEIN WEE1 INHIBITOR; RADICICOL; SMALL INTERFERING RNA; SNX 2112; SURVIVIN; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT;

EID: 84867257912     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.21926     Document Type: Article

References (27)

1. Trepel J, Mollapour M, Giaccone G, Neckers L. Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010; 10:537-49; PMID:20651736; http://dx.doi.org/10.1038/nrc2887.
2. Neznanov N, Komarov AP, Neznanova L, Stanhope-Baker P, Gudkov AV. Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.Oncotarget 2011; 2:209-21; PMID:21444945.
3. Tao YJ, Zheng W. Chaperones and the maturation of steroid hormone receptor complexes. Oncotarget 2011; 2:104-6; PMID:21399235.
4. Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 2012; 18:64-76; PMID:22215907; http://dx.doi.org/10.1158/ 1078-0432.CCR-11-1000.
5. Banerji U, Walton M, Raynaud F, Grimshaw R, Kelland L, Valenti M, et al. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Clin Cancer Res 2005; 11:7023-32; PMID:16203796; http://dx.doi.org/10.1158/1078-0432.CCR-05-0518.
6. Mollapour M, Tsutsumi S, Kim YS, Trepel J, Neckers L. Casein kinase 2 phosphorylation of Hsp90 threonine 22 modulates chaperone function and drug sensitivity. Oncotarget 2011.
7. Aligue R, Akhavan-Niak H, Russell P. A role for Hsp90 in cell cycle control: Wee1 tyrosine kinase activity requires interaction with Hsp90. EMBO J 1994; 13:6099-106; PMID:7813446.
8. Goes FS, Martin J. Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1. Eur J Biochem 2001; 268:2281-9; PMID:11298745; http://dx.doi.org/10.1046/j.1432-1327. 2001.02105.x.
9. Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee MJ, et al. Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. Mol Cell 2010; 37:333-43; PMID:20159553; http://dx.doi.org/10.1016/j.molcel.2010.01.005.
10. Mollapour M, Tsutsumi S, Neckers L. Hsp90 phosphorylation, Wee1 and the cell cycle. Cell Cycle 2010; 9:2310-6; PMID:20519952; http://dx.doi.org/10.4161/ cc.9.12.12054.
11. Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, et al. MK-1775, a small molecule Wee1 inhibitor, enhances antitumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther 2010; 9:514-22; PMID:20107315; http://dx.doi.org/10.4161/cbt.9.7.11115.
12. Kreahling JM, Gemmer JY, Reed D, Letson D, Bui M, Altiok SMK. MK1775, a selective Wee1 inhibitor, shows single-agent antitumor activity against sarcoma cells. Mol Cancer Ther 2012; 11:174-82; PMID:22084170; http://dx.doi.org/10. 1158/1535-7163.MCT-11-0529.
13. Guzman JR, Fukuda S, Pelus LM. Inhibition of caspase-3 by Survivin prevents Wee1 Kinase degradation and promotes cell survival by maintaining phosphorylation of p34Cdc2. Gene Ther Mol Biol 2009; 13B:264-73; PMID:20428502.
14. Kanwar JR, Kamalapuram SK, Kanwar RK. Survivin Signaling in Clinical Oncology: A Multifaceted Dragon. Med Res Rev 2012; PMID:22688671; http://dx.doi.org/10.1002/med.21264.
15. Kanwar JR, Mahidhara G, Kanwar RK. Antiangiogenic therapy using nanotechnological-based delivery system. Drug Discov Today 2011; 16:188-202; PMID:21262383; http://dx.doi.org/10.1016/j.drudis.2011.01.007.
16. Garrido C, Galluzzi L, Brunet M, Puig PE, Didelot C, Kroemer G. Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 2006; 13:1423-33; PMID:16676004; http://dx.doi.org/10.1038/sj.cdd.4401950.
17. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25:4798-811; PMID:16892092; http://dx.doi.org/10.1038/sj.onc.1209608.
18. Yano A, Tsutsumi S, Soga S, Lee MJ, Trepel J, Osada H, et al. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone. Proc Natl Acad Sci USA 2008; 105:15541-6; PMID:18840695; http://dx.doi.org/10.1073/pnas.0805354105.
19. Guha M, Altieri DC. Survivin as a global target of intrinsic tumor suppression networks. Cell Cycle 2009; 8:2708-10; PMID:19717980; http://dx.doi.org/10.4161/cc.8.17.9457.
20. Church DN, Talbot DC. Survivin in solid tumors: rationale for development of inhibitors. Curr Oncol Rep 2012; 14:120-8; PMID:22234703; http://dx.doi.org/10.1007/s11912-012-0215-2.
21. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008; 14:5000-5; PMID:18698017; http://dx.doi.org/10.1158/1078-0432.CCR-08-0746.
22. Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y, et al. Survivin is a therapeutic target in merkel cell carcinoma. Sci Transl Med 2012; 4:133ra56.
23. Giaccone G, Iacona RB, Fandi A, Janas M, Ochs JS, Herbst RS, et al. Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy. J Cancer Res Clin Oncol 2009; 135:467-76; PMID:18787840; http://dx.doi.org/10.1007/s00432-008-0466-3.
24. Garimella SV, Rocca A, Lipkowitz S. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Mol Cancer Res 2012; 10:75-85; PMID:22112940; http://dx.doi.org/10.1158/1541-7786.MCR-11-0500.
25. Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 2010; 122:347-57; PMID:19821025; http://dx.doi.org/10.1007/s10549-009-0571-2.
26. Palmer BD, Thompson AM, Booth RJ, Dobrusin EM, Kraker AJ, Lee HH, et al. 4-Phenylpyrrolo[3,4-c]car-bazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. J Med Chem 2006; 49:4896-911; PMID:16884302; http://dx.doi.org/10.1021/jm0512591.
27. Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, et al. Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment. Am J Pathol 2011; 179:2589-600; PMID:21933655; http://dx.doi.org/10.1016/j.ajpath.2011.07.035.